vs
ANGIODYNAMICS INC（ANGO）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
STURM RUGER & CO INC的季度营收约是ANGIODYNAMICS INC的1.9倍（$151.1M vs $79.4M），ANGIODYNAMICS INC同比增速更快（9.0% vs 3.6%），STURM RUGER & CO INC自由现金流更多（$12.3M vs $4.2M），过去两年STURM RUGER & CO INC的营收复合增速更高（5.1% vs 2.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
ANGO vs RGR — 直观对比
营收规模更大
RGR
是对方的1.9倍
$79.4M
营收增速更快
ANGO
高出5.4%
3.6%
自由现金流更多
RGR
多$8.1M
$4.2M
两年增速更快
RGR
近两年复合增速
2.8%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $151.1M |
| 净利润 | $-6.3M | — |
| 毛利率 | 56.4% | 17.8% |
| 营业利润率 | -7.7% | 2.3% |
| 净利率 | -8.0% | — |
| 营收同比 | 9.0% | 3.6% |
| 净利润同比 | 40.9% | — |
| 每股收益（稀释后） | $-0.15 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGORGR
| Q4 25 | $79.4M | $151.1M | ||
| Q3 25 | $75.7M | $126.8M | ||
| Q2 25 | $80.2M | $132.5M | ||
| Q1 25 | $72.0M | $135.7M | ||
| Q4 24 | $72.8M | $145.8M | ||
| Q3 24 | $67.5M | $122.3M | ||
| Q2 24 | $71.0M | $130.8M | ||
| Q1 24 | $75.2M | $136.8M |
净利润ANGORGR
| Q4 25 | $-6.3M | — | ||
| Q3 25 | $-10.9M | $1.6M | ||
| Q2 25 | $-6.0M | $-17.2M | ||
| Q1 25 | $-4.4M | $7.8M | ||
| Q4 24 | $-10.7M | — | ||
| Q3 24 | $-12.8M | $4.7M | ||
| Q2 24 | $-13.4M | $8.3M | ||
| Q1 24 | $-187.7M | $7.1M |
毛利率ANGORGR
| Q4 25 | 56.4% | 17.8% | ||
| Q3 25 | 55.3% | 15.1% | ||
| Q2 25 | 52.7% | 3.9% | ||
| Q1 25 | 54.0% | 22.0% | ||
| Q4 24 | 54.8% | 22.8% | ||
| Q3 24 | 54.4% | 18.5% | ||
| Q2 24 | 54.3% | 22.3% | ||
| Q1 24 | 47.7% | 21.5% |
营业利润率ANGORGR
| Q4 25 | -7.7% | 2.3% | ||
| Q3 25 | -14.1% | -2.7% | ||
| Q2 25 | -7.2% | -15.6% | ||
| Q1 25 | -13.9% | 6.2% | ||
| Q4 24 | -15.2% | 7.8% | ||
| Q3 24 | -19.4% | 3.1% | ||
| Q2 24 | -20.4% | 6.9% | ||
| Q1 24 | -265.9% | 5.5% |
净利率ANGORGR
| Q4 25 | -8.0% | — | ||
| Q3 25 | -14.4% | 1.2% | ||
| Q2 25 | -7.5% | -13.0% | ||
| Q1 25 | -6.1% | 5.7% | ||
| Q4 24 | -14.7% | — | ||
| Q3 24 | -19.0% | 3.9% | ||
| Q2 24 | -18.9% | 6.3% | ||
| Q1 24 | -249.7% | 5.2% |
每股收益（稀释后）ANGORGR
| Q4 25 | $-0.15 | $0.22 | ||
| Q3 25 | $-0.26 | $0.10 | ||
| Q2 25 | $-0.15 | $-1.05 | ||
| Q1 25 | $-0.11 | $0.46 | ||
| Q4 24 | $-0.26 | $0.62 | ||
| Q3 24 | $-0.31 | $0.28 | ||
| Q2 24 | $-0.35 | $0.47 | ||
| Q1 24 | $-4.67 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $283.8M |
| 总资产 | $269.7M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGORGR
| Q4 25 | $41.6M | $92.5M | ||
| Q3 25 | $38.8M | $80.8M | ||
| Q2 25 | $55.9M | $101.4M | ||
| Q1 25 | $44.8M | $108.3M | ||
| Q4 24 | $54.1M | $105.5M | ||
| Q3 24 | $55.0M | $96.0M | ||
| Q2 24 | $76.1M | $105.6M | ||
| Q1 24 | $78.5M | $115.3M |
总债务ANGORGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGORGR
| Q4 25 | $176.3M | $283.8M | ||
| Q3 25 | $178.9M | $279.6M | ||
| Q2 25 | $183.0M | $289.3M | ||
| Q1 25 | $185.9M | $321.5M | ||
| Q4 24 | $186.8M | $319.6M | ||
| Q3 24 | $196.6M | $314.9M | ||
| Q2 24 | $205.6M | $321.5M | ||
| Q1 24 | $218.7M | $332.0M |
总资产ANGORGR
| Q4 25 | $269.7M | $342.0M | ||
| Q3 25 | $265.6M | $342.3M | ||
| Q2 25 | $280.1M | $349.5M | ||
| Q1 25 | $285.4M | $379.0M | ||
| Q4 24 | $291.6M | $384.0M | ||
| Q3 24 | $293.6M | $373.5M | ||
| Q2 24 | $317.7M | $376.7M | ||
| Q1 24 | $324.8M | $385.0M |
负债/权益比ANGORGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $12.3M |
| 自由现金流率自由现金流/营收 | 5.3% | 8.2% |
| 资本支出强度资本支出/营收 | 0.5% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $38.5M |
8季度趋势，按日历期对齐
经营现金流ANGORGR
| Q4 25 | $4.7M | $15.5M | ||
| Q3 25 | $-15.9M | $12.9M | ||
| Q2 25 | $18.8M | $14.7M | ||
| Q1 25 | $-13.2M | $11.1M | ||
| Q4 24 | $2.5M | $20.0M | ||
| Q3 24 | $-18.3M | $9.4M | ||
| Q2 24 | $5.0M | $18.7M | ||
| Q1 24 | $-12.5M | $7.3M |
自由现金流ANGORGR
| Q4 25 | $4.2M | $12.3M | ||
| Q3 25 | $-16.6M | $7.0M | ||
| Q2 25 | $18.0M | $9.1M | ||
| Q1 25 | $-15.0M | $10.0M | ||
| Q4 24 | $1.7M | $16.4M | ||
| Q3 24 | $-19.3M | $2.6M | ||
| Q2 24 | $4.4M | $10.1M | ||
| Q1 24 | $-13.1M | $5.6M |
自由现金流率ANGORGR
| Q4 25 | 5.3% | 8.2% | ||
| Q3 25 | -22.0% | 5.5% | ||
| Q2 25 | 22.5% | 6.9% | ||
| Q1 25 | -20.8% | 7.4% | ||
| Q4 24 | 2.3% | 11.2% | ||
| Q3 24 | -28.7% | 2.1% | ||
| Q2 24 | 6.2% | 7.7% | ||
| Q1 24 | -17.5% | 4.1% |
资本支出强度ANGORGR
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 1.0% | 4.6% | ||
| Q2 25 | 1.0% | 4.2% | ||
| Q1 25 | 2.5% | 0.8% | ||
| Q4 24 | 1.1% | 2.5% | ||
| Q3 24 | 1.6% | 5.5% | ||
| Q2 24 | 0.8% | 6.6% | ||
| Q1 24 | 0.8% | 1.3% |
现金转化率ANGORGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
